Pro-Dex, Inc.

NasdaqCM:PDEX Rapport sur les actions

Capitalisation boursière : US$194.1m

Pro-Dex Croissance future

Future contrôle des critères 0/6

Les bénéfices de Pro-Dex devraient diminuer de 20.3% par an tandis que son chiffre d'affaires annuel devrait croître de 6.4% par an. Le BPA devrait croître de en baisse de 24.7% par an.

Informations clés

-20.3%

Taux de croissance des bénéfices

-24.71%

Taux de croissance du BPA

Medical Equipment croissance des bénéfices16.1%
Taux de croissance des recettes6.4%
Rendement futur des capitaux propresn/a
Couverture par les analystes

Low

Dernière mise à jour12 May 2026

Mises à jour récentes de la croissance future

Recent updates

Article d’analyse • Jan 10

We Think Pro-Dex (NASDAQ:PDEX) Can Manage Its Debt With Ease

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Article d’analyse • Nov 14

Even With A 26% Surge, Cautious Investors Are Not Rewarding Pro-Dex, Inc.'s (NASDAQ:PDEX) Performance Completely

Those holding Pro-Dex, Inc. ( NASDAQ:PDEX ) shares would be relieved that the share price has rebounded 26% in the last...
Article d’analyse • Sep 09

Earnings Working Against Pro-Dex, Inc.'s (NASDAQ:PDEX) Share Price Following 26% Dive

Pro-Dex, Inc. ( NASDAQ:PDEX ) shares have had a horrible month, losing 26% after a relatively good period beforehand...
Article d’analyse • Sep 06

We Think Pro-Dex (NASDAQ:PDEX) Can Stay On Top Of Its Debt

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Article d’analyse • Aug 13

With EPS Growth And More, Pro-Dex (NASDAQ:PDEX) Makes An Interesting Case

For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...
Article d’analyse • May 31

Pro-Dex, Inc.'s (NASDAQ:PDEX) 39% Dip In Price Shows Sentiment Is Matching Earnings

The Pro-Dex, Inc. ( NASDAQ:PDEX ) share price has softened a substantial 39% over the previous 30 days, handing back...
Article d’analyse • May 04

Here's Why Pro-Dex (NASDAQ:PDEX) Has Caught The Eye Of Investors

For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...
Article d’analyse • Apr 16

Pro-Dex, Inc.'s (NASDAQ:PDEX) P/E Is Still On The Mark Following 29% Share Price Bounce

Pro-Dex, Inc. ( NASDAQ:PDEX ) shares have continued their recent momentum with a 29% gain in the last month alone. The...
Article d’analyse • Apr 03

Pro-Dex (NASDAQ:PDEX) Looks To Prolong Its Impressive Returns

What are the early trends we should look for to identify a stock that could multiply in value over the long term...
Article d’analyse • Feb 24

This Analyst Just Made A Decent Upgrade To Their Pro-Dex, Inc. (NASDAQ:PDEX) Earnings Forecasts

Pro-Dex, Inc. ( NASDAQ:PDEX ) shareholders will have a reason to smile today, with the covering analyst making...
Article d’analyse • Feb 05

Some Pro-Dex, Inc. (NASDAQ:PDEX) Shareholders Look For Exit As Shares Take 27% Pounding

Pro-Dex, Inc. ( NASDAQ:PDEX ) shares have had a horrible month, losing 27% after a relatively good period beforehand...
Article d’analyse • Nov 13

This Analyst Just Made A Massive Upgrade To Their Pro-Dex, Inc. (NASDAQ:PDEX) Earnings Forecasts

Pro-Dex, Inc. ( NASDAQ:PDEX ) shareholders will have a reason to smile today, with the covering analyst making...
Article d’analyse • Nov 05

Pro-Dex, Inc. (NASDAQ:PDEX) Stock Rockets 31% As Investors Are Less Pessimistic Than Expected

Despite an already strong run, Pro-Dex, Inc. ( NASDAQ:PDEX ) shares have been powering on, with a gain of 31% in the...
Article d’analyse • Sep 10

Pro-Dex, Inc.'s (NASDAQ:PDEX) P/E Is Still On The Mark Following 37% Share Price Bounce

The Pro-Dex, Inc. ( NASDAQ:PDEX ) share price has done very well over the last month, posting an excellent gain of 37...
Article d’analyse • Jul 18

The Returns On Capital At Pro-Dex (NASDAQ:PDEX) Don't Inspire Confidence

Did you know there are some financial metrics that can provide clues of a potential multi-bagger? Ideally, a business...
Article d’analyse • Feb 16

Investors Can Find Comfort In Pro-Dex's (NASDAQ:PDEX) Earnings Quality

Pro-Dex, Inc.'s ( NASDAQ:PDEX ) earnings announcement last week didn't impress shareholders. While the headline numbers...
Article d’analyse • Feb 14

Here's Why Pro-Dex (NASDAQ:PDEX) Can Manage Its Debt Responsibly

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Article d’analyse • Jan 24

Pro-Dex, Inc.'s (NASDAQ:PDEX) Price Is Right But Growth Is Lacking After Shares Rocket 26%

Pro-Dex, Inc. ( NASDAQ:PDEX ) shareholders have had their patience rewarded with a 26% share price jump in the last...
Article d’analyse • May 20

Pro-Dex (NASDAQ:PDEX) Has A Pretty Healthy Balance Sheet

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Article d’analyse • Oct 05

Pro-Dex (NASDAQ:PDEX) Could Be Struggling To Allocate Capital

If you're not sure where to start when looking for the next multi-bagger, there are a few key trends you should keep an...
Seeking Alpha • Sep 26

Pro-Dex: Growth Trends In Earnings, Return On Investment Contracting

Summary Following its FY22 numbers Pro-Dex continues to realize a softening set of fundamentals. Growth trends in earnings and return on investment have been contracting on a sequential basis throughout the pandemic. Valuations do not support substantial upside, in my estimation. Net-net I've rated PDEX a hold with a $14.30 price target which reflects 10.5x FY23 earnings estimates. Investment summary The market has been doing all of the talking in in FY22 and in doing so has been doing the heavy lifting for us stock pickers. If you consider the market to be somewhat efficient [we do], and are an avid believer in data-driven fundamentals [again], then you'd have to agree that there's been a sigh of relief with the unwinding of the high-beta, growth trade of FY20'–21'. Investors are finally paying attention to fundamentals again, and the resulting factor rotation into defensives, quality and the likes has seen a rapid drawdown in wildly valued companies. Whilst we can think tech and private equity all we want, of equal substance here is the health care and medical technology ("medtech") sector[s]. Of no fault of its own, the medical and surgical equipment domains caught a strong bid across FY21 even with weakening fundamentals across the time period. Case in point is Pro-Dex, Inc (PDEX) whereby investors rewarded narrative versus numbers during the pandemic. The stock trades around 52-week lows and continues to push lower as the market continues to deal with the overvalued pockets that still linger around to this day. I've found the company's fundamentals have been weakening over the past 2 years and that investors may have been correct in re-rating the stock to its lowest average market cap in around 2-years. Net-net, I rate PDEX a hold, and note valuations are supportive of this view along with the above-mentioned points. For a quick overview, the company designs and manufactures surgical devices used in the thoracic, orthopaedic and craniomaxillofacial ("CMF") markets. It manufactures multifunctional surgical drivers and shavers that use the company's 'adaptive torque-limiting technology' and other IP that is sells to distributors. It books revenue on this basis and here, I've gone a little deeper into the company's numbers to understand how it is spending its money, and what value it is creating on this. PDEX FY22 results illustrate market headwinds The company came in with a weak set of results in FY22 compared to the previous 12 months. Net sales of $42.04 million ("mm") came in on a 10.5% YoY growth schedule whereas the cost of this turnover increased 18.2% YoY to $28.9mm. This led gross margin to compress by ~440bps YoY to 31.2%. Moving down the P&L, and OPEX came in 11% lower than FY21 due to reduced selling expenditure and a 32% YoY reduction to R&D spend. As such, PDEX recognized some upward mobility in operating income to $5.1mm and brought this down to a net income of $3.855mm, well behind FY21's $5.82mm in net profit. However, I'd note FY21 included $2.47mm in 'other' income that wasn't booked in FY22, and removing this from the equation earnings actually stretched up by 15% YoY. Meanwhile, it printed a loss of $2.52mm in FCF for the year. PDEX's FCF bridge for the 12 months is seen in Exhibit 1. Medical device sales make up 81% of turnover for PDEX, made up of revenue from orthopaedic, CMF and thoracic segments. Orthopaedic sales lifted 21.9% YoY and printed $21.87mm and made up 64% of total medical device turnover. Exhibit 1. Note: All figures in $mm. (Data: HB Insights, PDEX SEC Filings) PDEX fair view of fundamentals Deeper analysis on the company's FY22 numbers illustrate that concentration risk from customer's increased YoY. To illustrate, PDEX's top 3 customers attributed 88% of sales compared to 91% the year prior. However, there was 1 customer that accounted for ~66% of turnover, with the second largest customer generating 14%. Compared to FY21 the breakdown was 58% and 27% respectively. PDEX also had a backlog of $16.5mm at the end of FY22, and this was up 70.1% YoY and management said this is backed by firm purchase orders. Meanwhile, distribution of gross–operating profit has been lumpy on a sequential basis from FY20 to date, as seen in Exhibit 2. Similar trends are observed in free cash flow ("FCF") and FCF yield. Whereas PDEX recognized solid growth numbers from FY16–FY19 on a quarterly basis, this pattern has become less consistent throughout the pandemic, such that operating profit narrowed by CAGR 25.7% over this time. On this, TTM FCF yields have continued their descent from FY17, and PDEX realized a cumulative FCF loss of $10.75mm across the course of the pandemic. Exhibit 2. Reversal of [profit] growth trends from top to bottom line throughout pandemic. FCF yields continued descent – question becomes if there is the return on capital/investment to measure this as a positive result. Cumulative $10.75mm FCF loss across course of pandemic [quarterly]. Note: All figures in $mm or [%]. Free cash flow calculated as [NOPAT - investments]. FCF yield as a function of enterprise value on trailing twelve month basis. All calculations made from GAAP earnings with no reconciliations. (Image: HB Insights. Data: HB Insights, PDEX SEC Filings. ) The question then becomes if the FCF 'spend' has been realized back in the company's return on investment. In particular, I wanted to examine how much NOPAT the company generated from the previous period's invested capital. I've measured this as return on invested capital ("ROIC") and return on assets ("ROA") on a TTM basis. As seen in Exhibit 3, there is no divergence in the PDEX's return on investment to the FCF yield from FY20 to date. Both have been contracting in this time. Ideally, we'd see some bifurcation of ROIC and ROA to the upside, indicating that FCF was well 'spent' over the testing period, however this isn't the case in my estimation. From what we've observed so far in FY22, names that have been growing return on investment over the past 5 years have withstood the downside this YTD. Hence, this is an important factor in the PDEX investment debate. Exhibit 4. Positive correlation of PDEX's return on investment [ROIC, ROA], to FCF yield.
Article d’analyse • Sep 20

When Should You Buy Pro-Dex, Inc. (NASDAQ:PDEX)?

While Pro-Dex, Inc. ( NASDAQ:PDEX ) might not be the most widely known stock at the moment, it saw a decent share price...
Seeking Alpha • Aug 25

Pro-Dex GAAP EPS of $0.38, revenue of $12.61M

Pro-Dex press release (NASDAQ:PDEX): Q4 GAAP EPS of $0.38. Revenue of $12.61M (+33.6% Y/Y).
Article d’analyse • May 10

Is Now The Time To Look At Buying Pro-Dex, Inc. (NASDAQ:PDEX)?

Pro-Dex, Inc. ( NASDAQ:PDEX ), is not the largest company out there, but it received a lot of attention from a...
Article d’analyse • Apr 21

Is Pro-Dex (NASDAQ:PDEX) Using Too Much Debt?

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Article d’analyse • Mar 14

Pro-Dex (NASDAQ:PDEX) Is Doing The Right Things To Multiply Its Share Price

If we want to find a stock that could multiply over the long term, what are the underlying trends we should look for...
Article d’analyse • Feb 09

Is Pro-Dex, Inc. (NASDAQ:PDEX) Potentially Undervalued?

Pro-Dex, Inc. ( NASDAQ:PDEX ), might not be a large cap stock, but it saw significant share price movement during...
Article d’analyse • Nov 17

We Think Pro-Dex (NASDAQ:PDEX) Is Taking Some Risk With Its Debt

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...

Prévisions de croissance des bénéfices et des revenus

NasdaqCM:PDEX - Estimations futures des analystes et données financières antérieures (USD Millions )
DateRecettesLes revenusFlux de trésorerie disponibleCash from OpMoy. Nombre d'analystes
6/30/20278110N/A91
6/30/20267613N/A121
3/31/2026751277N/A
12/31/2025721166N/A
9/30/20257011-2-1N/A
6/30/2025679-3-2N/A
3/31/2025649-20N/A
12/31/202461723N/A
9/30/202457568N/A
6/30/202454256N/A
3/31/202449256N/A
12/31/202348334N/A
9/30/202347523N/A
6/30/202346745N/A
3/31/2023488-20N/A
12/31/2022447-4-3N/A
9/30/2022435-2-1N/A
6/30/2022425-3-1N/A
3/31/202239335N/A
12/31/2021415-21N/A
9/30/2021396-82N/A
6/30/2021386-10-2N/A
3/31/2021408-80N/A
12/31/2020367-43N/A
9/30/202036633N/A
6/30/202035645N/A
3/31/202031423N/A
12/31/2019294N/A4N/A
9/30/2019274N/A4N/A
6/30/2019274N/A3N/A
3/31/2019263N/A4N/A
12/31/2018253N/A3N/A
9/30/2018242N/A3N/A
6/30/2018222N/A3N/A
3/31/2018222N/A3N/A
12/31/2017232N/A4N/A
9/30/2017225N/A4N/A
6/30/2017225N/A3N/A
3/31/2017214N/A3N/A
12/31/2016204N/A2N/A
9/30/2016202N/A1N/A
6/30/2016191N/A0N/A
3/31/2016181N/A-1N/A
12/31/2015170N/A-1N/A
9/30/2015150N/A-2N/A
6/30/2015130N/A-1N/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: Les bénéfices de PDEX devraient diminuer au cours des 3 prochaines années ( -20.3% par an).

Bénéfices vs marché: Les bénéfices de PDEX devraient diminuer au cours des 3 prochaines années ( -20.3% par an).

Croissance élevée des bénéfices: Les bénéfices de PDEX devraient baisser au cours des trois prochaines années.

Chiffre d'affaires vs marché: Le chiffre d'affaires de PDEX ( 6.4% par an) devrait croître plus lentement que le marché de US ( 11.6% par an).

Croissance élevée des revenus: Le chiffre d'affaires de PDEX ( 6.4% par an) devrait croître plus lentement que 20% par an.

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

ROE futur: Données insuffisantes pour déterminer si le retour sur capitaux propres de PDEX devrait être élevé dans 3 ans

Découvrir les entreprises en croissance

7D

1Y

7D

1Y

7D

1Y

Analyse de l'entreprise et données financières

DonnéesDernière mise à jour (heure UTC)
Analyse de l'entreprise2026/05/20 01:18
Cours de l'action en fin de journée2026/05/20 00:00
Les revenus2026/03/31
Revenus annuels2025/06/30

Sources de données

Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.

PaquetDonnéesCadre temporelExemple de source américaine *
Finances de l'entreprise10 ans
  • Compte de résultat
  • Tableau des flux de trésorerie
  • Bilan
Estimations consensuelles des analystes+3 ans
  • Prévisions financières
  • Objectifs de prix des analystes
Prix du marché30 ans
  • Cours des actions
  • Dividendes, scissions et actions
Propriété10 ans
  • Actionnaires principaux
  • Délits d'initiés
Gestion10 ans
  • L'équipe dirigeante
  • Conseil d'administration
Principaux développements10 ans
  • Annonces de l'entreprise

* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.

Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.

Modèle d'analyse et flocon de neige

Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github; nous proposons également des guides expliquant comment utiliser nos rapports et des tutoriels sur Youtube.

Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.

Indicateurs de l'industrie et du secteur

Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.

Sources des analystes

Pro-Dex, Inc. est couverte par 1 analystes. 1 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.

AnalysteInstitution
Edward WooAscendiant Capital Markets LLC